{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Nagele MP"],"funding":["Universitätsspital Zürich","Swiss National Science Foundation","Schweizerische Herzstiftung"],"pagination":["e880"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9616169"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["5(6)"],"pubmed_abstract":["<h4>Background and aims</h4>Sustained neurohormonal activation plays a central role in the progression of heart failure (HF). Other endocrine axes may also be affected. It was the aim of this study to examine the endocrine profile (thyroid, parathyroid, glucocorticoid, and sex hormones) in a contemporary sample of patients with HF and reduced ejection fraction (EF) on established disease-modifying therapy.<h4>Methods</h4>This study prospectively measured morning fasting hormones in 52 ambulatory and stable HF patients with EF < 50% on disease-modifying therapy (mean age 63 ± 11 years, 29% female, mean LVEF 32 ± 9.6%) and compared them to 54 patients at elevated risk for HF (61 ± 12 years, 28% female) and 62 healthy controls (HC; 61 ± 13 years, 27% female). Main comparisons were performed u"],"journal":["Health science reports"],"pubmed_title":["Endocrine hormone imbalance in heart failure with reduced ejection fraction: A cross-sectional study."],"pmcid":["PMC9616169"],"funding_grant_id":["32003B_179161/1","179161"],"pubmed_authors":["Sudano I","Flammer AJ","Barthelmes J","Ruschitzka F","Nebunu D","Kreysing L","Haider T","Nagele MP"],"additional_accession":[]},"is_claimable":false,"name":"Endocrine hormone imbalance in heart failure with reduced ejection fraction: A cross-sectional study.","description":"<h4>Background and aims</h4>Sustained neurohormonal activation plays a central role in the progression of heart failure (HF). Other endocrine axes may also be affected. It was the aim of this study to examine the endocrine profile (thyroid, parathyroid, glucocorticoid, and sex hormones) in a contemporary sample of patients with HF and reduced ejection fraction (EF) on established disease-modifying therapy.<h4>Methods</h4>This study prospectively measured morning fasting hormones in 52 ambulatory and stable HF patients with EF < 50% on disease-modifying therapy (mean age 63 ± 11 years, 29% female, mean LVEF 32 ± 9.6%) and compared them to 54 patients at elevated risk for HF (61 ± 12 years, 28% female) and 62 healthy controls (HC; 61 ± 13 years, 27% female). Main comparisons were performed u","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-05T13:27:31.794Z","creation":"2025-02-19T01:30:10.74Z"},"accession":"S-EPMC9616169","cross_references":{"pubmed":["36320653"],"doi":["10.1002/hsr2.880"]}}